China Pharmaceutical announced that on July 31, 2026, its subsidiaries Tianfang Pharmaceutical and Sanyo Pharmaceutical participated in the 12th batch of centralized procurement bids for national drugs, and 8 products, including betahistine hydrochloride tablets, will be selected. The procurement cycle is 3 years, from the date of execution in 2026 to December 31, 2029. Some products had revenue in 2025 and the first half of 2026, such as betahistine hydrochloride tablets of about 10.79 million yuan in 2025 and 3.76 million yuan in the first half of 2026. The rest were newly launched products without sales. If the bid is won, the scale of sales will be expanded, but the purchase agreement has not been signed, and there is uncertainty about the future.

China Pharmaceutical announced that on July 31, 2026, its subsidiaries Tianfang Pharmaceutical and Sanyo Pharmaceutical participated in the 12th batch of centralized procurement bids for national drugs, and 8 products, including betahistine hydrochloride tablets, will be selected. The procurement cycle is 3 years, from the date of execution in 2026 to December 31, 2029. Some products had revenue in 2025 and the first half of 2026, such as betahistine hydrochloride tablets of about 10.79 million yuan in 2025 and 3.76 million yuan in the first half of 2026. The rest were newly launched products without sales. If the bid is won, the scale of sales will be expanded, but the purchase agreement has not been signed, and there is uncertainty about the future.